Anvisa Approves Medicine with Insulin and Semaglutide - 28/09/2026 - Equilibrio E Saúde
11 Articles
11 Articles
Kyinsu is indicated for adults who do not achieve glycaemic control with other medicines
semaglutide, ozempic Freepik The National Agency for Health Surveillance (Anvisa) approved the registration of Kyinsu, a medicine of the New Nordisk that combines insulin icodeca and semaglutide in a single solution for injection. The decision was published in the Official Journal of the Union (DOU) on Monday (28). According to the European Medicines Agency, Kyinsu is a medicine used in the treatment of type 2 diabetes. It is recommended mainly …
Unpublished registration brings together two active principles in single daily application for adults with type 2 diabetes mellitus; marketing depends on precision The post Anvisa releases 1st pen for weekly diabetes that combines semaglutide with insulin; know who can use it and when it arrives at the pharmacies apareceu primeiro em ND More
Kyinsu is indicated for adults with type 2 diabetes and gathers in a single weekly application basal insulin and GLP-1 agonist. Read on Power360.
Medicinal product, known as Kyinsu, is usually recommended for use in adults with the disease.
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
